查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1668059

慢性腎臟病治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品類型、最終用戶、地區和競爭細分，2020-2030 年

Chronic Kidney Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Product Type, By End User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球慢性腎臟病治療市場價值 354 億美元，預計在預測期內將保持穩定成長，到 2030 年的複合年成長率為 4.70%。 CKD 是一種進行性且通常無症狀的疾病，如果不及時治療，可能會導致腎衰竭。因此，CKD 治療市場在解決這一全球健康問題方面發揮關鍵作用。

市場概況
預測期 2026-2030
2024 年市場規模 354億美元
2030 年市場規模 467.4 億美元
2025-2030 年複合年成長率 4.70％
成長最快的領域 診斷部分
最大的市場 北美洲

主要市場促進因素

慢性腎臟病 (CKD) 及相關合併症盛行率上升

主要市場挑戰

經濟障礙和醫療保健差距

主要市場趨勢

個人化醫療和精準護理

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球慢性腎臟病治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依產品類型（診斷、治療、透析、其他）
    • 按最終使用者（醫院、診斷實驗室、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第 6 章：北美慢性腎臟病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第 7 章：歐洲慢性腎臟病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太慢性腎臟病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 按國家
  • 亞太地區：國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲慢性腎臟病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲慢性腎臟病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 13 章：全球慢性腎臟病治療市場：SWOT 分析

第 14 章：競爭格局

  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sysmex Corporation
  • Teva Pharmaceutical Industries Ltd.

第 15 章：策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 17682

Global Chronic Kidney Disease Treatment Market was valued at USD 35.40 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 4.70% through 2030. The Global Chronic Kidney Disease (CKD) Treatment Market is a critical component of the broader healthcare industry, encompassing a wide range of medical interventions, therapies, and medications aimed at managing and improving the quality of life for individuals affected by CKD. CKD is a progressive and often asymptomatic condition that can lead to kidney failure if left untreated. As such, the CKD Treatment Market plays a pivotal role in addressing this global health concern.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 35.40 Billion
Market Size 2030USD 46.74 Billion
CAGR 2025-20304.70%
Fastest Growing SegmentDiagnosis Segment
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Chronic Kidney Disease (CKD) and Related Comorbidities

The increasing global prevalence of Chronic Kidney Disease (CKD) is a fundamental driver of the Global CKD Treatment Market, as it directly fuels demand for pharmaceuticals, dialysis services, renal replacement therapies, and specialized healthcare services. This rising disease burden is largely attributed to several interconnected factors, including aging populations, lifestyle-related disorders, and genetic predispositions. Chronic Kidney Disease is a progressive and irreversible condition that affects millions worldwide. The 2023 ISN-GKHA multinational study on the global burden of kidney disease reports that approximately 850 million people worldwide are affected by Chronic Kidney Disease (CKD). The findings highlight that CKD impacts individuals across all age groups and racial backgrounds, with a disproportionately higher prevalence among economically disadvantaged populations. These insights emphasize the urgent need for targeted healthcare policies, improved access to early diagnosis, and expanded treatment infrastructure, particularly in high-risk and underserved communities, with a significant portion of cases remaining undiagnosed until the later stages. This expanding patient population is a major catalyst for the growth of the CKD treatment market. Improved screening programs and awareness campaigns are leading to earlier diagnoses, increasing demand for medications and lifestyle management interventions. Among patients without proteinuria data, the CKD diagnosis rate was 5.9%, with a significantly lower rate of 2.9% in stage G2. In contrast, for patients with quantitative proteinuria test results, the diagnosis rates were 43.5% overall and 31.3% in stage G2. These findings underscore the critical role of quantitative proteinuria testing in early CKD detection, highlighting a significant gap in diagnosis rates when such data is unavailable. This reinforces the need for wider adoption of advanced diagnostic protocols to improve CKD identification and clinical decision-making.

Key Market Challenges

Economic Barriers and Healthcare Disparities

One of the primary challenges is the economic disparity that exists globally. Access to advanced CKD treatments and medications often requires significant financial resources. High healthcare costs, including expenses related to dialysis, transplantation, and specialized medications, can be prohibitive for individuals with limited financial means.

In many regions, healthcare coverage and insurance options may not adequately address CKD treatment costs. Patients without comprehensive insurance may face difficulties in accessing essential treatments, which can lead to delayed or suboptimal care. Vulnerable populations, such as low-income individuals and underserved communities, are disproportionately affected by economic barriers. This can result in delayed CKD diagnosis, limited access to specialized care, and poorer outcomes.

Key Market Trends

Personalized Medicine and Precision Care

Personalized medicine is gaining prominence in the CKD treatment market. Healthcare providers are increasingly customizing treatment plans to meet the specific needs of individual CKD patients. This approach takes into account factors such as the patient's stage of CKD, comorbidities, genetic factors, and response to previous treatments.

Biomarker research plays a crucial role in personalizing CKD treatment. Biomarkers, such as specific proteins or genetic markers, are used to predict disease progression and treatment efficacy. This trend enables healthcare professionals to make more informed decisions about treatment strategies, including medication selection and dosing. Advances in genomics are revolutionizing CKD care. Genetic testing can identify genetic mutations or predispositions that influence CKD risk and progression. This information allows for the development of targeted therapies and interventions, with the potential to slow or halt disease progression in individuals with specific genetic profiles.

Key Market Players

  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sysmex Corporation
  • Teva Pharmaceutical Industries Ltd

Report Scope:

In this report, the Global Chronic Kidney Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Kidney Disease Treatment Market, By Product Type:

  • Diagnosis
  • Treatment
  • Dialysis
  • Others

Chronic Kidney Disease Treatment Market, By End User:

  • Hospitals
  • Diagnostic Laboratories
  • Others

Chronic Kidney Disease Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Kidney Disease Treatment Market.

Available Customizations:

Global Chronic Kidney Disease Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chronic Kidney Disease Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Diagnosis, Treatment, Dialysis, Others)
    • 5.2.2. By End User (Hospital, Diagnostic Laboratories, Other)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Chronic Kidney Disease Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Chronic Kidney Disease Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Chronic Kidney Disease Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Chronic Kidney Disease Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By End User

7. Europe Chronic Kidney Disease Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Chronic Kidney Disease Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By End User
    • 7.3.2. United Kingdom Chronic Kidney Disease Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By End User
    • 7.3.3. Italy Chronic Kidney Disease Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By End User
    • 7.3.4. France Chronic Kidney Disease Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Chronic Kidney Disease Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By End User

8. Asia-Pacific Chronic Kidney Disease Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By End User
  • 8.2.3 By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Chronic Kidney Disease Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Chronic Kidney Disease Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Chronic Kidney Disease Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Chronic Kidney Disease Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Chronic Kidney Disease Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By End User

9. South America Chronic Kidney Disease Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Chronic Kidney Disease Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Chronic Kidney Disease Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Chronic Kidney Disease Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By End User

10. Middle East and Africa Chronic Kidney Disease Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Chronic Kidney Disease Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Chronic Kidney Disease Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By End User
    • 10.3.3. UAE Chronic Kidney Disease Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Chronic Kidney Disease Treatment Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. AbbVie Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Amgen Inc.
  • 14.3. Bayer AG
  • 14.4. Bristol-Myers Squibb Company
  • 14.5. F. Hoffmann-La Roche Ltd
  • 14.6. GlaxoSmithKline PLC
  • 14.7. Merck & Co. Inc.
  • 14.8. Pfizer Inc.
  • 14.9. Sysmex Corporation
  • 14.10. Teva Pharmaceutical Industries Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer